- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00701376
Hepatic Effects of Gastric Bypass Surgery
Long Term Hepatic Effects of Gastric Bypass Surgery
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Before or on the day of surgery liver function will be determined using the DDG-2001 Analyzer. This monitor is able to detect the concentration of a dye called indocyanine green dye (ICG) when present in the blood stream. A dose of 0.5 mg/kg of ICG will be injected into an IV in the arm. Over approximately fifteen minutes the DDG-2001 Analyzer will determine how quickly the liver removes the dye ICG from the blood stream. This value represents how well the liver is functioning. Blood samples are drawn before injection of ICG to measure liver function using standard liver function tests.
This same routine for injecting ICG and obtaining blood for routine liver function tests will happen one more time, after surgery, once the subject has lost a significant amount of the original weight (60% of excess weight). This amount of weight loss typically occurs between 12 to 18 months after gastric bypass surgery. This second ICG measurement will occur during an outpatient follow-up visit to CCF.
A biopsy will be taken from the liver during surgery. A second biopsy taken after the 60% weight loss will be compared to determine the effect of this surgery on the liver.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44159
- Cleveland Clinic
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- BMI > 40.
- Documented failed non-surgical treatment for morbid obesity.
- Ability to undergo long-term follow-up after LGBS.
Exclusion Criteria:
- BMI < 40.
- Subject age < 18 years.
- Inability to undergo long-term follow-up after LGBS (living distance > 300 miles).
- Patients with known ESLD.
- Patients found to have evidence of ESLD during preoperative evaluation for LGBS including portal hypertension, ascites, and coagulopathy.
- Patients with known iodine sensitivity or allergy.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Muut: liver function
Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
|
Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Aspartate Transaminase (AST) Change
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
To assess the liver function change from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
Alanine Transaminase (ALT) Change
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
To assess the liver function change from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
Alkaline Phosphate (ALK)
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
To assess the liver function change from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
Total Bilirubin
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
To assess the liver function change from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure
|
Albumin
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
To assess the change in liver function from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
Prothrombin Time (PT)
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
To assess the change in liver function from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
Partial Thromboplastin Time (PTT)
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
To measure the change of PTT from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
Indocyanine Green (ICG) K Value
Aikaikkuna: from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
To assess the liver function change from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure).
ICG-k value is the slope of the decay curve of the serum ICG clearance graph, which is used to assess the liver function as it represents the rate of disappearance of ICG from blood as the liver exclusively distracts it.
The lower k value means a lower rate of ICG clearance, indicating a worse liver function.
|
from before surgery to the time when they lost 60% of their preoperative excess weight or weight loss had plateaued after this procedure (after the procedure minus versus before the procedure)
|
Number of Subjects of Nonalcoholic Steatohepatitis (NAS Steatosis)
Aikaikkuna: when patients lost 60% of their preoperative excess weight or weight loss had plateaued.
|
To compare the distribution of NAS steatosis stage from before surgery to when patients lost 60% of their preoperative excess weight or weight loss had plateaued.
The NAFLD activity score (NAS) from the NASH clinical Clinic Research Network is the unweighted sum of scores for steatosis, lobular inflammation, and ballooning hepatocyte degeneration, and ranges from zero to eight points.
The histological reporting for grading steatosis was based on a scale of 0 to 3, with 0 being no steatosis (<5%), 1 being mild steatosis (involving 5-33% of the biopsy specimen), 2 being moderate steatosis (involving 34-66% of the specimen), and 3 being severe (involving >66%).
|
when patients lost 60% of their preoperative excess weight or weight loss had plateaued.
|
Number of Subjects of Nonalcoholic Steatohepatitis Lobular Inflammation
Aikaikkuna: when patients lost 60% of their preoperative excess weight or weight loss had plateaued.
|
Lobular inflammation was similarly scored by number of foci per 200× magnification field (0 no foci: 1 < 2 foci: 2, 2-4 foci; 3, >4 foci) on biopsy specimen under microscope.
This outcome was compared on its distribution before the surgery and once patients lost 60% of their preoperative excess weight or weight loss had plateaued.
|
when patients lost 60% of their preoperative excess weight or weight loss had plateaued.
|
Fibrosis
Aikaikkuna: after surgery once they lost 60% of their preoperative excess weight or weight loss had plateaued
|
Fibrosis was measured from before surgery to after surgery once they lost 60% of their preoperative excess weight or weight loss had plateaued through biopsies
|
after surgery once they lost 60% of their preoperative excess weight or weight loss had plateaued
|
Nonalcoholic Steatohepatitis (NAS) Hepatocyte Balloon
Aikaikkuna: once patients lost 60% of their preoperative excess weight or weight loss had plateaued after surgery
|
Ballooning hepatocyte degeneration was scored as 0 (absent), 1 (few, difficult to identify), 2 (many, easily identified).
This was to assess the change in the distribution of NAS hepatocyte ballon between before the surgery and once patients lost 60% of their preoperative excess weight or weight loss had plateaued
|
once patients lost 60% of their preoperative excess weight or weight loss had plateaued after surgery
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Diagnostic Accuracy-AST
Aikaikkuna: before RYGB surgery
|
AST was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Diagnostic Accuracy-ALT
Aikaikkuna: before RYGB surgery
|
ALT was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate and the y-axis is the true positive rate.
The AUC of ROC represents the performance of diagnostic measures/models, the higher score means better performance in general.
The range of AUC is from 0 to 1.0.
|
before RYGB surgery
|
Diagnostic Accuracy-ALK
Aikaikkuna: before RYGB surgery
|
ALK was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate and the y-axis is the true positive rate.
The AUC of ROC represents the performance of diagnostic measures/models, the higher score means better performance in general.
The range of AUC is from 0 to 1.0.
|
before RYGB surgery
|
Diagnostic Accuracy-total Bilirubin
Aikaikkuna: before RYGB surgery
|
The total bilirubin was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC of ROC represents the performance of diagnostic measures/models, the higher score means better performance in general.
The range of AUC is from 0 to 1.0.
|
before RYGB surgery
|
Diagnostic Accuracy-PT
Aikaikkuna: before RYGB surgery
|
PT was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Diagnostic Accuracy-PTT
Aikaikkuna: before RYGB surgery
|
PTT (Partial Thromboplastin Time) was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Diagnostic Accuracy-ICG k Value
Aikaikkuna: before RYGB surgery
|
ICG k value was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Diagnostic Accuracy-albumin
Aikaikkuna: before RYGB surgery
|
Albumin was measured before RYGB surgery and was used to fit a univariate logistic model to predict clinically asymptomatic but significant fatty liver, including NASH and NASH plus fibrosis.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 99.4% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Diagnostic Accuracy-multiple Factor
Aikaikkuna: before RYGB surgery
|
We also built a multivariable model using all preoperative liver function tests and ICG k clearance values to predict NASH (nonalcoholic steatohepatitis) from pre-RYGB values.
AUC was used to assess the prediction performance of those multiple factors.
The AUC (area under the curve) of the receiver operating characteristic curve (ROC) was calculated with a 95% confidence interval.
The x-axis of ROC is the false positive rate (%) and the y-axis is the true positive rate (%).
The AUC value of ROC represents the performance of diagnostic measures/models, the higher value means better performance in general.
The range of AUC is from 0 to 1.0 (perfect performance).
|
before RYGB surgery
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Brian M. Parker, MD, The Cleveland Clinic
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 07-877
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Maksasairaudet
-
Grand Valley State UniversityIlmoittautuminen kutsustaMetaboliseen aineenvaihduntaan liittyvä dysfunction Steatotic Liver Disease (MASLD) | Aineenvaihduntaan liittyvä steatohepatiitti (MASH)Yhdysvallat
-
University of UlsanUlsan University HospitalTuntematonToksokariaasi | Silmän toksokariaasi | Keuhkojen toksokariaasi | Hiottu lasin opasiteetti (GGO) | Toxocara Canis -infektio (koiran pyöreät madot) | Law Liver | Law Meat | Seerumin Toxocara vasta-aine | Toxocara Larva MigransKorean tasavalta
Kliiniset tutkimukset liver biopsy
-
Centre Hospitalier Universitaire de NiceRekrytointi
-
Assistance Publique Hopitaux De MarseilleAktiivinen, ei rekrytointiEi-pienisoluiset keuhkosyöpäpotilaatRanska
-
Aquyre Bioscience, IncBoston University; Fox Chase Cancer Center; Johnson & JohnsonRekrytointi
-
Vital Therapies, Inc.PeruutettuAkuutti maksan vajaatoiminta
-
Indiana UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrytointiMaksasairaudetYhdysvallat
-
NeoDynamics ABRekrytointiRintasyöpäYhdistynyt kuningaskunta
-
Owlstone LtdValmisKeuhkosyöpäYhdistynyt kuningaskunta
-
The Cleveland ClinicAktiivinen, ei rekrytointi
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrytointiUudet kystisen fibroosin transmembraanisen konduktanssin säätimen (CFTR) toiminnon merkit hikoilussaKystinen fibroosi | BiomarkkeritBelgia
-
City of Hope Medical CenterNational Cancer Institute (NCI)ValmisGenito-virtsateiden kasvainYhdysvallat